busulfan has been researched along with Preleukemia in 5 studies
Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 5.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 1.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gyger, M | 1 |
| Perreault, C | 1 |
| Boileau, J | 1 |
| Aymard, JP | 1 |
| Bonny, Y | 1 |
| Lacombe, M | 1 |
| Lavallee, R | 1 |
| d'Angelo, G | 1 |
| Tawil, E | 1 |
| Stuart, J | 1 |
| Locatelli, F | 1 |
| Pession, A | 1 |
| Bonetti, F | 1 |
| Maserati, E | 1 |
| Prete, L | 1 |
| Pedrazzoli, P | 1 |
| Zecca, M | 1 |
| Prete, A | 1 |
| Paolucci, P | 1 |
| Cazzola, M | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Pedersen-Bjergaard, J | 1 |
| Ersbøll, J | 1 |
| Sørensen, HM | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Larsen, MS | 1 |
| Schultz, H | 1 |
| Nissen, NI | 1 |
1 trial available for busulfan and Preleukemia
| Article | Year |
|---|---|
Chemotherapy of the myeloid leukaemias.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as | 1980 |
4 other studies available for busulfan and Preleukemia